<DOC>
	<DOCNO>NCT00151840</DOCNO>
	<brief_summary>The efficacy safety liquid intravenous immunoglobulin product , IVIG-L , patient ITP assess compare data obtain literature .</brief_summary>
	<brief_title>Efficacy Safety IVIG-L ITP Patients</brief_title>
	<detailed_description>Sanquin develop , cooperation Finnish Red Cross Blood Transfusion Service ( FRCBTS ) , liquid intravenous immunoglobulin product , IVIG-L . The liquid formulation intravenous immunoglobulin simplifies infusion , eliminate possible mistake reconstitution water injection reduces space requirement storage . In addition donor selection screening , several procedure include production process improve viral safety . In clinical trial , efficacy safety IVIG-L patient ITP assess compare data obtain literature . IVIG-L also study patient hypogammaglobulinemia.The result study use application marketing authorisation IVIG-L Finland Netherlands .</detailed_description>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Patients chronic ITP platelet count 20x109/L high risk bleed Patients chronic ITP platelet count 20x109/L , undergo surgery A stable clinical situation ( activity disease ) Age least 18 yr The patient/legally acceptable representative sign consent form The presence another autoimmune disease relate thrombocytopenia systematic lupus erythematosus ( SLE ) , rheumatoid arthritis ( RA ) nephritis Patients druginduced thrombocytopenia immunologic thrombocytopenia infectious origin ( particular , Hepatitis , EpsteinBarr virus , Toxoplasma , HIV ) Massive splenomegaly Treatment investigational drug within 7 day study entry previous enrolment study Having ongoing progressive terminal disease , include HIV infection Known allergic reaction human plasma , plasma product intravenous immunoglobulin Presence condition predispose bleeding : anaemia ( hemoglobin &lt; 5.5 mmol/L ) , renal urogenital disease , malignant disease ( exception basalioma , cervix carcinoma situ ) , history intracranial aortic aneurysm , stroke , oesogastrointestinal disorder bleed potential , severe hypertension ( diastole &gt; 110 mm Hg ) . Use corticosteroid acute situation within 7 day study entry . Patients use corticosteroid prophylactically include Splenectomy previous two week Renal insufficiency ( plasma creatinine &gt; 115Âµmol/L ) Pregnancy lactation Known insufficiency coronary cerebral circulation IgA deficiency antiIgA antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>Purpura , Thrombocytopenic , Idiopathic</keyword>
	<keyword>ITP</keyword>
	<keyword>Immunoglobulin , Intravenous</keyword>
</DOC>